JAMA Network
About The Study: In this cohort study of women with benign uterine pathology or endometrial hyperplasia, combined glucagon-like peptide-1 receptor agonist (GLP-1RA) and progestin was associated with reduced endometrial cancer risk. Further investigation is warranted to assess its applicability and underlying mechanisms.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
